Molecular biomonitoring of a population of nurses handling antineoplastic drugs

Tommaso Cornetta1, Luca Padua, Antonella Testa

  • 1Department of Biology, Roma Tre University, Viale Guglielmo Marconi, 446-00146 Rome, Italy.

Mutation Research
|October 12, 2007
PubMed

Insights

Hospital nurses exposed to antineoplastic drugs show significant DNA and chromosome damage. Genetic variations, like XRCC1 polymorphism, may increase susceptibility to this occupational health risk.

Area of Science:

  • Occupational Health
  • Genetics
  • Toxicology

Background:

  • Antineoplastic drugs pose health risks (carcinogenic, mutagenic, teratogenic) to hospital personnel.
  • Occupational exposure to these agents necessitates understanding long-term health risks, even with protective measures.

Purpose of the Study:

  • To assess DNA and chromosome damage in oncology nurses exposed to antineoplastic drugs.
  • To investigate the influence of genetic polymorphisms (XRCC1, XRCC3) and confounding factors (smoking, age, gender) on induced genetic damage.

Main Methods:

  • Comet assay to detect DNA strand breaks from acute/chronic exposure.
  • Micronucleus (MN) test to measure clastogenic and aneugenic events.
  • Analysis of XRCC1 and XRCC3 single nucleotide polymorphisms (SNPs) and confounding factors.

Main Results:

  • Exposed nurses exhibited significantly higher levels of genetic damage compared to controls.
  • Age and gender correlated with increased MN values in both groups.
  • Smoking affected MN frequency in controls but not in exposed workers.
  • Individuals with XRCC1 variant allele (399Gln) showed higher MN values when exposed.

Conclusions:

  • Occupational exposure to antineoplastic drugs presents a significant health risk to healthcare workers, even under controlled conditions.
  • XRCC1 genetic polymorphism can exacerbate genetic damage in susceptible individuals exposed to these hazardous substances.

Related Concept Videos

Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Drug Concentrations: Measurements01:23

Drug Concentrations: Measurements

Drug concentration is the quantity of a drug present in a biological sample. Measuring drug amounts in biological samples allows the clinician to understand how a drug is absorbed, distributed, metabolized, and excreted. Samples can be obtained through invasive or non-invasive methods. Invasive techniques involve surgical or parenteral interventions to gather blood, cerebrospinal fluid, or tissue biopsy. Conversely, non-invasive approaches provide samples like urine, feces, and saliva.
Plasma —...
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...